Fuller H B vs Orion
FUL and OEC side by side, both in chemicals and allied products. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How FUL and OEC compare
Fuller H B is the larger company, worth 12 times as much as Orion ($2.7B against $226M).
Fuller H B grew revenue faster over the last twelve months (1.5% versus 0.86% for Orion).
Fuller H B keeps more of each dollar of sales as profit, with a net margin of 5.6% compared with −1.8% at Orion.
Both pay dividends: Fuller H B yields 2.0% and Orion 1.6%.
Fuller H B scores higher on the StockData Score (18 against 8 for Orion), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | FUL | OEC |
|---|---|---|
| Size and price | ||
| Market cap | $2.7B | $226M |
| Share price | $49.29 | $3.99 |
| Change, 1 year | −14.8% | −16.5% |
| Change, 5 years | −35.6% | −78.2% |
| Beta (5Y) | 0.95 | 1.06 |
| Employees | 7,100 | 1,650 |
| StockData Score | ||
| Total score | 18 (better) | 8 |
| Valuation score | 6 (better) | 4 |
| Growth score | 3 (better) | 0 |
| Performance score | 3 (better) | 0 |
| Health score | 2 | 2 |
| Dividend score | 4 (better) | 2 |
| Valuation | ||
| P/E | 13.7× | – |
| P/S | 0.7× | 0.1× (better) |
| P/B | 1.2× | 0.6× (better) |
| EV/EBITDA | 7.9× | 5.4× (better) |
| P/FCF | 26.5× | 5.2× (better) |
| FCF yield | 3.8% | 19.3% (better) |
| Fair value | $102.06 | $25.42 |
| Margin of safety | 51.7% | 84.3% (better) |
| Growth | ||
| Revenue growth (TTM) | 1.5% (better) | 0.86% |
| Revenue growth, 5Y average | 4.5% | 9.7% (better) |
| Net income growth (TTM) | 72.2% | – |
| EPS growth (TTM) | 71.8% | – |
| EPS growth, 5Y average | 3.1% | – |
| Profitability | ||
| Gross margin | 32.3% (better) | 18.5% |
| Operating margin | – | 4.0% |
| Net margin | 5.6% (better) | −1.8% |
| FCF margin | 2.8% (better) | 2.4% |
| Return on equity | 9.6% (better) | −8.1% |
| Return on invested capital | – | 2.7% |
| Financial health | ||
| Debt / equity | 0.95 (better) | 2.48 |
| Net debt / EBITDA | 3.35 (better) | 4.30 |
| Current ratio | 1.82 (better) | 1.06 |
| Altman Z-score | 1.85 (better) | 1.44 |
| Piotroski F-score | 7 (better) | 3 |
| Dividends and buybacks | ||
| Dividend yield | 2.0% (better) | 1.6% |
| Payout ratio | 26.2% | – |
| Years of dividend growth | 16 (better) | 0 |
| Dividend growth, 5Y average | 7.4% (better) | −16.7% |
| Buyback yield | 1.8% (better) | 0.35% |
| Shareholder yield | 3.8% (better) | 1.9% |
| Ownership | ||
| Held by institutions | 104% | 94.1% |
| Held by insiders | 0.65% | 4.1% |
| Insider net buying, 12 months | $853K | – |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 4.1% | 4.0% |
Go deeper
- FUL stock overview
- FUL income statement
- FUL valuation and score
- OEC stock overview
- OEC income statement
- OEC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.